Takeda ends DNL593 collaboration; Denali regains full rights
Takeda terminated its DNL593 partnership for strategic reasons, not safety. Denali regains full rights. The Phase 1/2 trial continues with 40 patients and data due end of 2026.
image from Gemini Imagen 4
Takeda has terminated its eight-year collaboration with Denali Therapeutics on DNL593, a progranulin replacement therapy for granulin-mutation frontotemporal dementia (FTD-GRN), returning full rights to Denali. The termination stems from Takeda's strategic portfolio recalibration rather than any efficacy or safety concerns, as the Phase 1/2 trial continues with 40 enrolled patients and interim data showing dose-dependent CSF progranulin increases. Denali expects to report Phase 1/2 results by end of 2026, maintaining full control of IP and development while the TransportVehicle platform—which enabled the first FDA-approved BBB-crossing biologic—provides the delivery backbone.
- •Takeda's exit reflects large pharma retrenchment around narrower therapeutic priorities, not a setback to DNL593's clinical profile; the drug continues to meet its pharmacodynamic endpoints
- •Phase 1/2 readout (Q4 2026) is a critical near-term catalyst for Denali's solo development path and investor sentiment around the FTD-GRN indication
- •The TransportVehicle platform's FDA approval status and royalty revenue did not insulate the partnered asset—platform credibility alone is insufficient to retain strategic partners
